<img alt="" height="1" width="1" />Salix Pharmaceuticals Reports 1Q2010 ResultsMarketWatch (press release)Data from the Company's Phase 3 pivotal trials evaluating rifaximin in patients with non-constipation irritable bowel syndrome received broad exposure and ...Salix Pharma 1Q Loss Widens; 2Q Guidance Strong<nobr>Wall Street Journal</nobr><nobr>all 30 news articles »</nobr> |